Kazmierczak S C, Catrou P G, Boudreau D
Department of Pathology and Laboratory Medicine, East Carolina University School of Medicine, Greenville, NC 27858-4354, USA.
Clin Chem. 1998 Nov;44(11):2347-52.
Substances such as hemoglobin that interfere with analytical processes are recognized as a frequent source of error in laboratory medicine. Standard guidelines for assessment of test interferences assume that interference effects are not related to the concentration of the analyte being measured. However, previous investigations have demonstrated that interference effects can be markedly different, depending on the concentrations of interferent and analyte within the specimen. An experimental protocol for investigating these different types of interference effects has been developed. This protocol utilizes an orthogonally arranged matrix with progressively increasing concentrations of analyte and interferent. Evaluation of the measured analyte concentrations in specimens within the matrix using multiple regression analysis allows the magnitude, direction, and significance of each type of interference to be determined. Unfortunately, implementation of the interference data derived from the multiple regression analysis for judging the clinical acceptability of test results when an interferent is present is difficult. We describe a two-dimensional graphical format for evaluating the clinical acceptability of test results, based on criteria established under the Clinical Laboratory Improvement Amendments of 1988, in specimens containing hemoglobin-based oxygen carrier solutions.
诸如血红蛋白等干扰分析过程的物质被认为是检验医学中常见的误差来源。检验干扰评估的标准指南假定干扰效应与所测分析物的浓度无关。然而,先前的研究表明,干扰效应可能会有显著差异,这取决于样本中干扰物和分析物的浓度。现已制定了一项用于研究这些不同类型干扰效应的实验方案。该方案采用正交排列的矩阵,其中分析物和干扰物的浓度逐渐增加。使用多元回归分析评估矩阵内样本中所测分析物的浓度,可确定每种干扰类型的大小、方向及显著性。遗憾的是,当存在干扰物时,将多元回归分析得出的干扰数据用于判断检验结果的临床可接受性很难。我们基于1988年《临床实验室改进修正案》规定的标准,描述了一种二维图形格式,用于评估含血红蛋白基氧载体溶液样本中检验结果的临床可接受性。